Why the study?
Does High-Sensitivity Cardiac Troponin T (hs-cTnT) measurement predict all-cause mortality in cancer patients before starting chemotherapy?
Does High-Sensitivity Cardiac Troponin T (hs-cTnT) measurement predict all-cause mortality in cancer patients before starting chemotherapy?
Baseline hs-cTnT measurement (using a cutoff of 7 ng/L) is an effective tool to stratify mortality risk in cancer patients prior to chemotherapy.
Answers are grounded in this paper and cite their sources.
May support pre-chemotherapy mortality stratification in cancer; hypothesis-generating and requires prospective validation.
Based on our non-selected cohort of cardio-oncological patients, hs-cTnT was able to identify patients with high mortality by using a low cutoff of 7 ng/L. We conclude that measurement of hs-cTnT is an important tool to stratify the risk for mortality of cancer patients before starting chemotherapy.
No takes yet. Share an insight, caveat, or question.
Finke et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: